Ischemic Heart Disease: Special Considerations in Cardio-Oncology
- 19 April 2017
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 19 (5) , 37
Abstract
The interplay and balance between the competing morbidity and mortality of cardiovascular diseases and cancer have a significant impact on both short- and long-term health outcomes of patients who survived cancer or are being treated for cancer. Ischemic heart disease in patients with cancer or caused by cancer therapy is a clinical problem of emerging importance. Prompt recognition and optimum management of ischemic heart disease mean that patients with cancer can successfully receive therapies to treat their malignancy and reduce morbidity and mortality due to cardiovascular disease. In this sense, the presence of cancer and cancer-related comorbidities (e.g., thrombocytopenia, propensity to bleed, thrombotic status) substantially complicates the management of cardiovascular diseases in cancer patients. In this review, we will summarize the current state of knowledge on the management strategies for ischemic disease in patients with cancer, focusing on the challenges encountered when addressing these complexities.Keywords
This publication has 70 references indexed in Scilit:
- Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosisProceedings of the National Academy of Sciences, 2012
- Treatment and Outcomes of Acute Coronary Syndrome in the Cancer PopulationClinical Cardiology, 2012
- Arterial and Venous Thrombosis in Cancer PatientsCardiology Research and Practice, 2011
- Cardiotoxicity with 5‐fluorouracil and capecitabine: more than just vasospastic anginaInternal Medicine Journal, 2010
- Thromboembolic events with lenalidomide‐based therapy for multiple myelomaCancer, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromesCancer, 2006
- Cardiovascular Complications of Cancer TherapyCirculation, 2004
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999